Abstract
Introduction
Cancer stem cells have been implicated angiogenesis of tumor and invasiveness, drug resistance in tumors. Yes-associated protein 1 (YAP) owns carcinogenic roles in various organs, but the role of YAP in cancer stem cells of gastric cancer (GC) remains unclear. In this study, we explored the function and mechanism of YAP in GC cancer stem cells.
Materials and methods, and results
First, we confirmed that the expression of YAP mRNA and protein in GC tissues was higher than in adjacent tissues by RT-PCR, western blot and immunohistochemistry. Immunofluorescence staining of the GC tissues revealed that the region of YAP expression coincided with the region of expression of the cancer stem cell marker SALL4 but did not overlap with that of the epithelial marker cytokeratin 14 (CK14). Additional research revealed that spherical cells expressed relatively high levels of YAP protein, and YAP overexpression reinforced self-renewal and expression of stem cell markers in the GC cells. Knockdown the expression of YAP reversed this phenomenon. Second, we examined the expression patterns of lipocalin-type prostaglandin D2 synthase (L-PTGDS) and prostaglandin D2 receptor 2 (PTGDR2) in GC tissues and proved that there was negatively correlation between the expression of L-PTGDS and PTGDR2 and YAP in GC tissues. Finally, we confirmed that YAP inhibited the expression of L-PTGDS and PTGDR2 by gain- and loss-of-function experiments. Moreover, the overexpression of L-PTGDS and PTGDR2 suppressed the proliferation and self-renewal induced by YAP in vitro and reversed the pro-tumor effect of YAP in vivo.
Conclusion
Our results revealed a novel function of YAP and the mechanism underlying cancer stem cell regulation by YAP.
This is a preview of subscription content, access via your institution.






Data availability
The various raw data and methods used to support the findings of this study are available from the corresponding author upon request.
References
Yuan WC, Pepe-Mooney B, Galli GG et al (2018) NUAK2 is a critical YAP target in liver cancer. Nat Commun 9:4834
Song Z, Wu Y, Yang J et al (2017) Progress in the treatment of advanced gastric cancer. Tumour Biol 39:1010428317714626
Lee HS, Kim WH, Kwak Y et al (2017) Molecular Testing for Gastrointestinal Cancer. J Pathol Transl Med 51:103–121
Shi P, Wan J, Song H et al (2018) The emerging role of circular RNAs in gastric cancer. Am J Cancer Res 8:1919–1932
Ye J, Xu J, Li Y et al (2017) DDAH1 mediates gastric cancer cell invasion and metastasis via Wnt/beta-catenin signaling pathway. Mol Oncol 11:1208–1224
Xie H, Wu L, Deng Z et al (2018) Emerging roles of YAP/TAZ in lung physiology and diseases. Life Sci 214:176–183
Segrelles C, Paramio JM, Lorz C (2018) The transcriptional co-activator YAP: a new player in head and neck cancer. Oral Oncol 86:25–32
Qiu B, Wei W, Zhu J et al (2018) EMT induced by loss of LKB1 promotes migration and invasion of liver cancer cells through ZEB1-induced YAP signaling. Oncol Lett 16:6465–6471
Hsu HT, Estaras C, Huang L et al (2018) Specifying the anterior primitive streak by modulating YAP1 levels in human pluripotent stem cells. Stem Cell Rep 6:1357–1364
Choi W, Kim J, Park J et al (2018) YAP/TAZ initiates gastric tumorigenesis via upregulation of MYC. Cancer Res 78:3306–3320
Pan Z, Tian Y, Zhang B et al (2017) YAP signaling in gastric cancer-derived mesenchymal stem cells is critical for its promoting role in cancer progression. Int J Oncol 51:1055–1066
Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31:986–1000
Bie Q, Dong H, Jin C et al (2018) 15d-PGJ2 is a new hope for controlling tumor growth. Am J Transl Res 10:648–658
Iwanaga K, Nakamura T, Maeda S et al (2014) Mast cell-derived prostaglandin D2 inhibits colitis and colitis-associated colon cancer in mice. Cancer Res 74:3011–3019
Zhang B, Bie Q, Wu P et al (2018) PGD2/PTGDR2 signaling restricts the self-renewal and tumorigenesis of gastric cancer. Stem Cells 36:990–1003
Yan H, Qiu C, Sun W et al (2018) Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy. Oncol Rep 39:1671–1681
Zhang L, Xu Z, Xu X et al (2014) SALL4, a novel marker for human gastric carcinogenesis and metastasis. Oncogene 33:5491–5500
Shibue T, Weinberg RA (2017) EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14:611–629
Park JH, Shin JE, Park HW (2018) The role of hippo pathway in cancer stem cell biology. Mol Cells 41:83–92
Lang T, Ding X, Kong L et al (2018) NFATC2 is a novel therapeutic target for colorectal cancer stem cells. Onco Targets Ther 11:6911–6924
Zhao AY, Dai YJ, Lian JF et al (2018) YAP regulates ALDH1A1 expression and stem cell property of bladder cancer cells. Onco Targets Ther 11:6657–6663
Zhang B, Gong A, Shi H et al (2017) Identification of a novel YAP-14-3-3ζ negative feedback loop in gastric cancer. Oncotarget 8:71894–71910
Santoro R, Zanotto M, Carbone C et al (2018) MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity. Anticancer Res 38:1937–1946
Escoll M, Gargini R, Cuadrado A et al (2017) Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP/TAZ. Oncogene 36:3515–3527
Kulkarni M, Tan TZ, Syed Sulaiman NB et al (2018) RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer. Oncotarget 9:14175–14192
Zhu G, Wang Y, Mijiti M et al (2015) Upregulation of miR-130b enhances stem cell-like phenotype in glioblastoma by inactivating the Hippo signaling pathway. Biochem Biophys Res Commun 465:194–199
Hu Y, Shin DJ, Pan H et al (2017) YAP suppresses gluconeogenic gene expression through PGC1alpha. Hepatology 66:2029–2041
House CD, Jordan E, Hernandez L et al (2017) NFkappaB promotes ovarian tumorigenesis via classical pathways that support proliferative cancer cells and alternative pathways that support ALDH(+) cancer stem-like cells. Cancer Res 77:6927–6940
Dai Y, Liu S, Zhang WQ et al (2017) YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells. Oncotarget 8:4096–4109
Omori K, Morikawa T, Kunita A et al (2018) Lipocalin-type prostaglandin D synthase-derived PGD2 attenuates malignant properties of tumor endothelial cells. J Pathol 244:84–96
Murata T, Aritake K, Matsumoto S et al (2011) Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci USA 108:19802–19807
Acknowledgements
This study was supported by grants from National Natural Science Foundation of China (No. 81702439, 81802446), Tai Shan Young Scholar Foundation of Shandong Province (NO.tsqn201909192), Shandong Provincial Natural Science Foundation (No. ZR2019BH050). Supported by PhD Research Foundation of Affiliated Hospital of Jining Medical University (No. 2018-BS-001, 2018-BS-013), the Project of Health and Family Planning Commision of Shandong province (NO. 2017WS513), Supporting Fund for Teachers' research of Jining Medical University (NO.JYFC2018FKJ035). This manuscript was edited by Wallace Academic Editing.
Funding
The authors declare no competing financial interests.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Bie, Q., Li, X., Liu, S. et al. YAP promotes self-renewal of gastric cancer cells by inhibiting expression of L-PTGDS and PTGDR2. Int J Clin Oncol 25, 2055–2065 (2020). https://doi.org/10.1007/s10147-020-01771-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-020-01771-1
Keywords
- Yes-associated protein 1
- Prostaglandin D2 synthase
- Prostaglandin D2 receptor 2
- Gastric
- Cancer stem cell